- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2017 · career development · Young Investigator Award
Genomic Risk Prediction Assay Use and Outcomes in Young Women with Early-Stage Breast Cancer
Philip Poorvu · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2017 · research · SU2C Innovative Research Grant (Class of 2017)
IDENTIFYING AND TARGETING MECHANISMS OF RESISTANCE TO IMMUNOTHERAPY
Rizwan Haq · Dana-Farber Cancer Institute · funded by Stand Up To Cancer
2017 · fellowship · AACR-AstraZeneca Fellowship in Ovarian Cancer Research
Investigation of PARP inhibitor resistance in BRCA1-mutant ovarian tumors
Yizhou J. He · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2017 · career development · Career Development Award
Overcoming drug resistance in MET exon 14 mutant non-small cell lung cancer
Mark Awad · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2017 · career development · Career Development Award
Epigenetic priming prior to checkpoint blockade to induce an anti-leukemia immune response
Jacqueline Garcia · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2017 · fellowship · Gianni Bonadonna Breast Cancer Research Fellowship
Identifying risk of recurrence in patients with residual disease after neoadjuvant therapy for triplenegative breast cancer
Ana Garrido-Castro · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2017 · career development · Young Investigator Award
Translational Discovery in Angioimmunoblastic T-cell Lymphoma
Samuel Ng · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2017 · fellowship · ASH Research Training Award for Fellows (RTAF): Junior Awardees
ASH Research Training Award for Fellows (RTAF) 2017: Hojun Li
Hojun Li · Dana-Farber Cancer Institute · funded by American Society of Hematology
2017 · fellowship · Debbie’s Dream Foundation-AACR Gastric Cancer Research Fellowship
RHOA alterations in the development of diffuse gastric cancer
Haisheng Zhang · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2017–2027 · research · R01
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2027 · research · R01
Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity
Kimmie Ng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2028 · cooperative agreement · U24
Cancer Immune Monitoring and Analysis Center
Frank S Hodi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P50
Targeting SF3B1 for the treatment of MDS
Benjamin Levine Ebert · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P01
Program Integration
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P50
CORRELATIVE SCIENCE CORE
Jon C. Aster · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P01
CORE 2: Administrative Core
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P01
Core 1: Functional Proteomics
Jarrod A. Marto · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P50
Career Enhancement Program
Timothy A Graubert · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P01
PROJECT 1: Merkel Cell Carcinoma, Merkel Cell Polyomavirus and PP2A (James A. DeCaprio)
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P50
Targeting MLL/Menin in AML
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P50
BIOSPECIMENS AND XENOGRAFT
Jerome Ritz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P50
Targeting SYK Kinase in AML
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P50
Administrative Core A
Benjamin Levine Ebert · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P01
PROJECT 2: Oncogenic Transformation via the PP2A/YAP/Hippo pathway
Thomas M Roberts · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P50
Core 1: Biostatistics
Donna S. Neuberg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P01
PROJECT 4: Interrogating PP2A Signaling in Human Cancers
William C. Hahn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P01
PROJECT 3: Pathways Controlled by PP2A A-Beta in Normal, Transformed and Tumor Cells
Brian S Schaffhausen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2017 · career development · K99
The role of circulating Slit2 in adipose thermogenesis and diabetes
Katrin Jennifer Svensson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Targeting Immunogenicity to the MPER Hinge and C-helix for BNAb Elicitation
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R00
The Role of EglN1 and HIF in Normal Hematopoiesis and in Leukemia
Julie-Aurore Losman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · research · R13
The Third International Molecular Pathological Epidemiology (MPE) Meeting
Shuji Ogino · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2020 · fellowship · F31
Structure-Function Analysis of a Novel Inhibitory Mechanism for Pro-Apoptotic BAK
Zachary Joel Hauseman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Novel functions of D-type and E-type cyclins in normal and in cancer cells
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · cooperative agreement · U01
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection
Brian Matthew Wolpin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Conformational Landscape of the HIV-1 Envelope Glycoproteins
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K07
Video Informed Consent Tools to Improve Care for Patients With Advanced Pancreatic Cancer
Andrea C Enzinger · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
